
Cathie Wood’s ARK Invest has been steadily dialing down its exposure to mega-cap tech, trimming names like Nvidia (NVDA), Meta (META), AMD (AMD), and Tesla (TSLA) amid valuation and regulatory concerns. But at the same time, the firm is rotating capital into smaller, high-upside opportunities. Recently, it added nearly 48,700 shares of Arcturus Therapeutics (ARCT) worth roughly $344,505.
Let’s find out why.